AR075437A1 - Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento - Google Patents
Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamentoInfo
- Publication number
- AR075437A1 AR075437A1 ARP100100442A ARP100100442A AR075437A1 AR 075437 A1 AR075437 A1 AR 075437A1 AR P100100442 A ARP100100442 A AR P100100442A AR P100100442 A ARP100100442 A AR P100100442A AR 075437 A1 AR075437 A1 AR 075437A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunogenic composition
- adjuvant
- dengue
- virus
- vaccine
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 10
- 239000000203 mixture Substances 0.000 title abstract 10
- 239000002671 adjuvant Substances 0.000 title abstract 6
- 208000001490 Dengue Diseases 0.000 title abstract 5
- 206010012310 Dengue fever Diseases 0.000 title abstract 5
- 208000025729 dengue disease Diseases 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title 1
- 229910052782 aluminium Inorganic materials 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003995 emulsifying agent Substances 0.000 abstract 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 2
- 239000007764 o/w emulsion Substances 0.000 abstract 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 229940087168 alpha tocopherol Drugs 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 229960000984 tocofersolan Drugs 0.000 abstract 1
- 239000002076 α-tocopherol Substances 0.000 abstract 1
- 235000004835 α-tocopherol Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composicion inmunogénica que comprende al menos un antígeno del virus del dengue inactivado que se selecciona entre el grupo consistente en antígenos del virus Dengue-1, Dengue-2, Dengue- 3 y Dengue-4 y un adyuvante sin aluminio. Método para producir dicha vacuna. Su uso para preparar un medicamento util para prevenir, mejorar o tratar una enfermedad producida por el virus del dengue. Reivindicacion 4: La composicion inmunogénica de cualquiera de las reivindicaciones 1 a 3, caracterizada porque el adyuvante comprende una emulsion de aceite en agua. Reivindicacion 5: La composicion inmunogénica de cualquiera de las reivindicaciones 1 a 4, caracterizada porque el adyuvante comprende un vehículo de emulsion de aceite en agua que comprende un aceite metabolizable, un tocol y un emulsionante. Reivindicacion 6: La composicion inmunogénica de la reivindicacion 4 o 5, caracterizada porque el aceite metabolizable es escualeno. Reivindicacion 7: La composicion inmunogénica de cualquiera de las reivindicaciones 5 o 6, caracterizada porque el tocol es alfa-tocoferol. Reivindicacion 8: La composicion inmunogénica de cualquiera de las reivindicaciones 4 a 7, caracterizada porque la emulsion comprende un emulsionante tensioactivo no ionico. Reivindicacion 9: La composicion inmunogénica de reivindicacion 8, caracterizada porque el tensioactivo no ionico es monooleato de polioxietileno sorbitano. Reivindicacion 17: La composicion inmunogénica de la reivindicacion 15, caracterizada porque el adyuvante comprende además colesterol. Reivindicacion 18: La composicion inmunogénica de cualquiera de las reivindicaciones 15 a 17, caracterizada porque el adyuvante comprende además 1,2-dioleoil-sn-glicero-3-fosfocolina (DOPC).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15306009P | 2009-02-17 | 2009-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075437A1 true AR075437A1 (es) | 2011-03-30 |
Family
ID=42174405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100442A AR075437A1 (es) | 2009-02-17 | 2010-02-16 | Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9265821B2 (es) |
| EP (1) | EP2398821B1 (es) |
| JP (2) | JP6058266B2 (es) |
| KR (1) | KR101738704B1 (es) |
| CN (1) | CN102395600B (es) |
| AR (1) | AR075437A1 (es) |
| AU (1) | AU2010215595A1 (es) |
| BR (1) | BRPI1011224A2 (es) |
| CA (1) | CA2752809A1 (es) |
| CL (1) | CL2011001993A1 (es) |
| CO (1) | CO6551750A2 (es) |
| DO (1) | DOP2011000268A (es) |
| ES (1) | ES2649020T3 (es) |
| IL (1) | IL214385A (es) |
| MX (1) | MX338898B (es) |
| NZ (1) | NZ700477A (es) |
| PE (2) | PE20151588A1 (es) |
| PH (1) | PH12015501637A1 (es) |
| SG (2) | SG173194A1 (es) |
| TW (2) | TW201517915A (es) |
| UY (1) | UY32457A (es) |
| WO (1) | WO2010094663A1 (es) |
| ZA (1) | ZA201105656B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1011224A2 (pt) * | 2009-02-17 | 2016-03-15 | Glaxosmithkline Biolog Sa | vacina contra vírus da dengue inativado com adjuvante livre de alumínio |
| WO2011027222A2 (en) | 2009-09-02 | 2011-03-10 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| EP2719395A1 (en) | 2010-09-01 | 2014-04-16 | Novartis AG | Adsorption of immunopotentiators to insoluble metal salts |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| KR20140033171A (ko) * | 2011-05-26 | 2014-03-17 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 비활성화된 뎅기 바이러스 백신 |
| CA2866406A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| BE1024160B9 (fr) | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
| WO2017197035A1 (en) | 2016-05-10 | 2017-11-16 | Najit Technologies, Inc. | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process |
| JP7195147B2 (ja) * | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Ｐｅｇ化リポソームおよび使用方法 |
| EP3558351B1 (en) * | 2016-12-23 | 2022-01-26 | Intervet International B.V. | Combination vaccine for swine |
| EP3678695A1 (en) * | 2017-09-08 | 2020-07-15 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
| EP3845639A4 (en) * | 2018-08-27 | 2022-05-11 | Mican Technologies Inc. | PROCEDURE FOR EVALUATION OF ANTIINFECTIVES, VACCINES ETC. USING IMMORTALIZED MONOCYTIC CELLS AND INDUCED CELLS |
| CN111150849A (zh) * | 2020-04-02 | 2020-05-15 | 广州隽沐生物科技股份有限公司 | 一种组合物及其制备方法及其应用 |
| CN114377122B (zh) * | 2022-01-18 | 2023-04-07 | 四川大学 | 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途 |
| WO2023147337A2 (en) * | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CZ289476B6 (cs) | 1993-03-23 | 2002-01-16 | Smithkline Beecham Biologicals (S.A.) | Očkovací přípravek a způsob jeho výroby |
| EP0729473B1 (en) | 1993-11-17 | 2000-08-23 | OM Pharma | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US6254873B1 (en) * | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| DE69838992T2 (de) * | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| EP1089913A1 (fr) | 1998-06-08 | 2001-04-11 | SCA Emballage France | Emballage a remise a plat rapide |
| AU761396B2 (en) | 1998-06-30 | 2003-06-05 | Om Pharma | Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
| SI1126876T1 (sl) * | 1998-10-16 | 2007-08-31 | Glaxosmithkline Biolog Sa | Adjuvantni sistemi in vakcine |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| WO2000057907A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Multivalent dengue virus vaccine |
| AU776638B2 (en) | 1999-03-26 | 2004-09-16 | Walter Reed Army Institute Of Research | Adaptation of virus to vertebrate cells |
| HK1044484B (en) * | 1999-04-19 | 2005-07-29 | Smithkline Beecham Biologicals S.A. | Adjuvant composition containing saponin and immunostimulatory oligonucleotide |
| WO2001046127A1 (fr) | 1999-12-22 | 2001-06-28 | Om Pharma | Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise |
| CA3114957C (en) | 2001-05-22 | 2022-02-08 | Stephen S. Whitehead | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| GB0304799D0 (en) | 2003-03-03 | 2003-04-09 | Glaxosmithkline Biolog Sa | Novel method |
| EP1942932B1 (en) | 2005-08-08 | 2013-05-08 | Oregon Health and Science University | Inactivating pathogens with hydrogen peroxide for vaccine production |
| JP4828189B2 (ja) * | 2005-09-14 | 2011-11-30 | 雅美 森山 | 分泌型ＩｇＡ及びＩｇＧ抗体誘導剤 |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| FR2896162B1 (fr) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| CN101522218B (zh) | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
| US20110150914A1 (en) * | 2008-06-09 | 2011-06-23 | La Jolla Institute For Allergy And Immunology | Compositions and methods for dengue virus (dv) treatment and vaccination |
| BRPI1011224A2 (pt) * | 2009-02-17 | 2016-03-15 | Glaxosmithkline Biolog Sa | vacina contra vírus da dengue inativado com adjuvante livre de alumínio |
-
2010
- 2010-02-16 BR BRPI1011224A patent/BRPI1011224A2/pt not_active IP Right Cessation
- 2010-02-16 NZ NZ700477A patent/NZ700477A/en not_active IP Right Cessation
- 2010-02-16 WO PCT/EP2010/051882 patent/WO2010094663A1/en not_active Ceased
- 2010-02-16 CN CN201080016827.1A patent/CN102395600B/zh not_active Expired - Fee Related
- 2010-02-16 JP JP2011549593A patent/JP6058266B2/ja not_active Expired - Fee Related
- 2010-02-16 SG SG2011055068A patent/SG173194A1/en unknown
- 2010-02-16 MX MX2011008649A patent/MX338898B/es active IP Right Grant
- 2010-02-16 SG SG2014014385A patent/SG2014014385A/en unknown
- 2010-02-16 EP EP10709443.5A patent/EP2398821B1/en active Active
- 2010-02-16 KR KR1020117021610A patent/KR101738704B1/ko not_active Expired - Fee Related
- 2010-02-16 PE PE2015001630A patent/PE20151588A1/es not_active Application Discontinuation
- 2010-02-16 PE PE2011001431A patent/PE20110992A1/es not_active Application Discontinuation
- 2010-02-16 US US13/148,741 patent/US9265821B2/en not_active Expired - Fee Related
- 2010-02-16 AR ARP100100442A patent/AR075437A1/es unknown
- 2010-02-16 AU AU2010215595A patent/AU2010215595A1/en not_active Abandoned
- 2010-02-16 CA CA2752809A patent/CA2752809A1/en not_active Abandoned
- 2010-02-16 ES ES10709443.5T patent/ES2649020T3/es active Active
- 2010-02-17 UY UY0001032457A patent/UY32457A/es not_active Application Discontinuation
- 2010-02-22 TW TW103135137A patent/TW201517915A/zh unknown
- 2010-02-22 TW TW099104980A patent/TWI528972B/zh active
-
2011
- 2011-08-01 IL IL214385A patent/IL214385A/en not_active IP Right Cessation
- 2011-08-01 ZA ZA2011/05656A patent/ZA201105656B/en unknown
- 2011-08-16 CL CL2011001993A patent/CL2011001993A1/es unknown
- 2011-08-19 DO DO2011000268A patent/DOP2011000268A/es unknown
- 2011-08-30 CO CO11111072A patent/CO6551750A2/es not_active Application Discontinuation
-
2015
- 2015-06-22 JP JP2015125077A patent/JP6104988B2/ja not_active Expired - Fee Related
- 2015-07-23 PH PH12015501637A patent/PH12015501637A1/en unknown
-
2016
- 2016-01-11 US US14/992,354 patent/US20160120972A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075437A1 (es) | Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento | |
| AR053360A1 (es) | Formulaciones novedosas de vacunas | |
| NO20090062L (no) | Influensavaksine | |
| CO6251369A2 (es) | Vacuna de influenza de emulsion de aceite en agua | |
| IL185897A (en) | Use of influenza virus or antigenic agent derived from the first influenza virus strain and adjuvant of water emulsion for the preparation of a vaccine for the protection against influenza strain caused by a variant influenza when the water emulsion contains squalene, alpha-tocopherol and emulsifier | |
| UA107940C2 (en) | The vaccine composition that includes the saponin-containing adjuvant | |
| CY1108994T1 (el) | Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα | |
| CA2664619C (en) | Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| AR036039A1 (es) | Composicion de vacuna para el virus de la influenza | |
| CY1108782T1 (el) | Νεες συνταγοποιησεις εμβολιου | |
| CL2007001698A1 (es) | Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis. | |
| AR073452A1 (es) | Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis | |
| AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
| CO6251273A2 (es) | Composiciones para vacuna en emulsion que comprenden antigeno y un adyuvante en la fase acuosa y su metodo de elaboracion | |
| NZ600323A (en) | Circulation of components during microfluidization and/or homogenization emulsions | |
| DOP2010000188A (es) | Una vacuna de vih que comprende una proteina y un agente estabilizador | |
| EA201001478A1 (ru) | Вакцина | |
| Gan et al. | Different serotypes of dengue viruses differently regulate the expression of the host cell antigen processing machinery | |
| AR077832A1 (es) | Metodo para suspender un flavonoide en una bebida | |
| CY1113746T1 (el) | Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ | |
| MX360271B (es) | Una emulsion que contiene una sustancia medicinal no viva. | |
| MX2009010963A (es) | Vacuna de influenza de emulsion de aceite en agua. | |
| DOP2009000068A (es) | Vacuna que comprende un adyuvante de emulsión de aceite en agua | |
| UY29523A1 (es) | Formulaciones de vacunas novedosas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |